美因基因2023中期报告

( 於開曼群島註冊成立的有限公司 )股份代號: 6667 中 期 報 告2023 24615273233353638 ᙑ່ 122 97927 818 Third Floor, Century YardCricket Square, P.O. Box 902Grand Cayman, KY1-1103Cayman Islands 公司༟ࣘ 401 6667 3485 www.megagenomics.cn Appleby Global Services (Cayman) Limited71 Fort StreetPO Box 500George TownGrand Cayman KY1-1106Cayman Islands 1617 20162023630172023630180,000 202112312020 2023 2022610 20236309786 大眾普通型 ••••• 中端實惠型 ••Septin9•RNF180/Septin9• ุਕΫᚥʿ࢝ૐ 尊貴定制型 •Plus•(i)(ii) IVD (i)(ii)ApoE(iii)BRCA1/BRCA2 (i)(ii)(iii)(iv)(v)(vi)(vii) ApoE基因檢測試劑盒 ApoEqPCRApoEApoEApoEϵ4 2022531,2002024 葉酸代謝能力評估檢測試劑盒 qPCRMTHFR 2022531,2002024 阿爾茨海默症篩查試劑盒 miRNA1,500 RT-qPCRNGS NGS(LDT) RT-qPCR2025 結直腸癌篩查試劑盒 DNA 202363031,500 qPCRNGS NGSLDT qPCR2024 胃癌篩查試劑盒 DNA 202363031,500 qPCRNGS NGSLDT qPCR2024 ุਕΫᚥʿ࢝ૐ BRCA1/BRCA2基因突變檢測試劑盒 BRCA1/BRCA2PCR 2023630IVD cfDNA2023 20162023202260% 知識產權和資質 20236304158 內部研發團隊 65% 與第三方合作 IVDIVD IVDCROIVD 2023630 IVD CDMOCDMOIVDPCR CRO ุਕΫᚥʿ࢝ૐ PCRqPCRNGSPCR IVDApoEIVDBRCA1/BRCA2 PCRqPCRNGSPCR50,000 880PCR2022 98.91.3%35.197.3% 20236303401,77053% 202363098.9202297.61.31.3%202363057.041.92023 ุਕΫᚥʿ࢝ૐ 202363065.31.4%33.332.041.1% 202363066.0%202363076.4%2.158.4%6.6 202020300.8%11.6% 2023 ၍ଣᄴীሞʿʱؓ 20226302023 ၍ଣᄴীሞʿʱؓ •202363057.025.1% •202363041.919.6% 202263033.21.1%202333.6 2022202363064.465.366.0% ၍ଣᄴীሞʿʱؓ •202263023.6202333.3202263051.8%202358.4% •202263040.8202332.0 20226303.8103.0%20237.8 202263015.84.7%202316.520221229 202263014.863.8%202324.220221229 20226300.2202363010.4 202220236301.10.2 20226300.434.5%20230.3 20226303.0141.0%20237.2 202263017.8202335.1 202363067.3 202363018.2 202363019.6 20221231399.87.7%2023630430.7 ၍ଣᄴীሞʿʱؓ 2022622 20221231202363011.010.6 2023630 202363020221231 202363010.7%2022123112.4%1.7 (1)(2)(3) ၍ଣᄴীሞʿʱؓ 2023630 2023630 2023630 2023630 2023630 2023630267 202363029.2202226.8 202111192022122927,272,000202212299.92022122910.52022122813.12 (a)目的 (b)參與者範圍 (i)(ii)(iii) (c)期限 20236309 (d)股份最高數目 20226127,272,00011.4%2022122927,272,000100% (e)個人上限及行使期 ၍ଣᄴীሞʿʱؓ (f)所授出受限制股份單位的歸屬時間表 (1)(2)(3) (g)受限制股份單位行使價格的釐定基礎 1. (a)(b)(c) 2. (a)(b)(c) 3. 4.17.07 2022 2023630 Չ˼༟ࣘ 13.51B(1) 2023721 2023630XVXV78352 (1)2023630YURONG TECHNOLOGY LIMITED100%(i)99%(ii)1%YURONG TECHNOLOGY LIMITED (2)2023630Infinite Galaxy Health LimitedInfiniteGalaxy Health Limited2021811InfiniteGalaxy HealthLimitedInfiniteGalaxy Health Limited)InfiniteGalaxy Health LimitedInfinite Galaxy Health Limited (4)2023630LINLIN DJK HOLDING LTD.LINLINDJKHOLDING LTD. : (1)2023630 (2)20229812.73%12.29% Չ˼༟ࣘ 2023630XV23336 (1)2023630Mei Nian Investment Limited100%Mei Nian Investment Limited (2)2023630MegaMarvelous Limited 100%Mega Marvelous Limited (3)2023630YURONG TECHNOLOGY LIMITED100%(i)99%(ii)1%YURONG TECHNOLOGY LIMITED (4)2023630Infinite Galaxy Health LimitedInfiniteGalaxy Health Limited2021811InfiniteGalaxy Health LimitedInfinite Galaxy Health LimitedInfiniteGalaxy Health Limited (5)2023630(i)99.90%(ii)0.10%99.90%0.10%99.87% (6)2023630239,233,800 2023630336 2023630 20226221811,961,800215.3153.42023630 Չ˼༟ࣘ 2023630 2023630 3.213.10(2)3.21 202363034 未經審核中期簡明綜合損益及其他全面收益表 2023630 ͊຾ᄲࣨʕಂᔊ׼ၝΥৌਕًڌر 2023630 2023630 ͊຾ᄲࣨʕಂᔊ׼ၝΥᛆूᜊਗڌ 2023630 2023630 ͊຾ᄲࣨʕಂᔊ׼ၝΥତݴږඎڌ 2023630 2023630 1. 20236303420221231 2. 20221231 171717 179 1281212 (a)12202311 (b)8202311 ͊຾ᄲࣨʕಂᔊ׼ၝΥৌਕ༟ࣘڝൗ 2023630 2. (c)1212 (d)1220231120231231 3. 4. (a)分拆收入資料 ͊຾ᄲࣨʕಂᔊ׼ၝΥৌਕ༟ࣘڝൗ 2023630 4. (b)履約責任 5. 6. 16.5% 25%15% ͊຾ᄲࣨʕಂᔊ׼ၝΥৌਕ༟ࣘڝൗ 2023630 6. 7. 2022630 8. 221,052,4672022200,594,786 2022630 2023630 8. ͊຾ᄲࣨʕಂᔊ׼ၝΥৌਕ༟ࣘڝൗ 2023630 9. 2023630144,666,0002022162,266,000 10. 33661212 2023630297,0002022195,000 11. ͊຾ᄲࣨʕಂᔊ׼ၝΥৌਕ༟ࣘڝൗ 2023630 12. 12. (b) ͊຾ᄲࣨʕಂᔊ׼ၝΥৌਕ༟ࣘڝൗ 2023630 12. (c) 13. 2023630 13. 按公平值計量的資產： 2023630 202363020221231 2022630 14.